The importance of education and collaboration for the treatment of patients

This article is written in the context of EHA’s membership of the European Alliance for Personalised Medicine (EAPM) where EHA takes a lead in the development of a strategy for education in personalized medicine. Read the full article here

EHA mapping of adolescent and young adult (AYA) hematology patient care

EHA has launched a major consultation to understand patient care for Adolescents and Young Adults (AYA) with hematological diagnoses across Europe.

Addressing immunoglobulin shortages: EHA and EBA’s strategic recommendations at the EMA

In recent years, shortages of immunoglobulins (Ig) have become a growing concern in the European Union (EU). Since 2018, the European Medicines Agency (EMA)—the EU agency that evaluates and supervises medicines—has received an increasing number of shortage reports.

In Memoriam Anneke Brand

Picture: Ineke Oostveen

 

On Sunday, November 21, 2021, Anneke Brand, MD, PhD, emeritus professor at Leiden University Medical Center (LUMC), passed away suddenly. The European Hematology Association community is deeply saddened by Anneke’s passing.

Topics-in-Focus program

How malignant cells in patients with Chronic Lymphocytic Leukemia escape T cell recognition and attack

T cell activation is essential for immunity including the recognition and killing of abnormal target cells such as cancerous cells.

EHA-SWG Scientific Meeting “Developing a research agenda for transfusion in Europe”

On September 15-17, 2022, the EHA-SWG Scientific Meeting “Developing a research agenda for transfusion in Europe” was successfully held at the Occidental Praha hotel in Prague, Czechia.

Press Release: Economic burden of blood disorders in EU is €23 billion

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.